Cat. No.: HY-141480

GSK-3β inhibitor 3

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia.

For research use only. We do not sell to patients.

Purity: 99.22%
CAS No.: 1448990-73-5
Formula: C₁₈H₁₄FNO₂S
Molecular Weight:327.37

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

GSK-3β inhibitor 3 Chemical Structure

CAS No.: 1448990-73-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

GSK-3β

6.6 μM (IC₅₀)

All GSK-3 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	86.3 μM Compound: 45385	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 34027661]
MOLT-4	IC₅₀	75.58 μM Compound: 45385	Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 34027661]
NB-4	IC₅₀	19.56 μM Compound: 45385	Cytotoxicity against human NB-4 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human NB-4 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 34027661]
NB4-DR1	IC₅₀	26.42 μM Compound: 45385	Antiproliferative activity against human NB4-DR1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NB4-DR1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 34027661]
Raji	IC₅₀	28.45 μM Compound: 45385	Cytotoxicity against human Raji cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human Raji cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 34027661]

In Vitro

GSK-3β inhibitor 3 (compound 4-3) (100 μM) inhibits GSK-3α activity by 87.3%^[1].
GSK-3β inhibitor 3 (6.25-100 μM; 24-48 h) dose-dependently inhibits the growth of NB4 and NB4-R1 cells^[1].
GSK-3β inhibitor 3 (12.5-100 μM; 24 h) significantly increases the percentage of apoptosis in a dose-dependent pattern in NB4 and NB4-R1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

NB4 and NB4-R1 cells
Concentration:

6.25, 12.5, 25, 50, 100 μM
Incubation Time:

24, 48 hours
Result:

Inhibited the cell viability, with IC₅₀s of 19.56 μM and 26.42 μM in NB4 and NB4-R1 cells at 24 h, respectively.
Had little cytotoxicity on human normal liver cells (LO₂) and human umbilical vein endothelial cells (HUVECs).

Apoptosis Analysis^[1]

Cell Line:

NB4 and NB4-R1 cells
Concentration:

12.5, 25, 50, 100 μM
Incubation Time:

24 hours
Result:

Induced cell apoptosis.

In Vivo

GSK-3β inhibitor 3 (compound 4-3) (15 mg/kg/d; i.p. for 2 weeks) inhibits tumor growth of mice by 75.97% relative to vehicle control^[1].
GSK-3β inhibitor 3 (15 mg/kg; a single i.p.) shows long T_1/2 of 14.2 h, high AUC values (AUC_last=3503.42 ng/mL h), and maximum concentration (C_max=515 ng/mL) in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c female nude mice were injected leukemia cells^[1]
Dosage:

15 mg/kg/d
Administration:

I.p. for 2 weeks
Result:

Inhibited localized growth in NB4 cells.
Had mild weight loss compared with control.

Animal Model:

Male ICR mice (30 g)^[1]
Dosage:

15 mg/kg (Pharmacokinetic Analysis)
Administration:

A single i.p.
Result:

T_1/2=14.2 h; AUC_last=3503.42 ng/mL•h; C_max=515 ng/mL.

Chemical Information

CAS No. 1448990-73-5
Appearance Solid
Molecular Weight 327.37
Formula C₁₈H₁₄FNO₂S
Color White to off-white
SMILES

FC(C=C1)=CC=C1C2CC(N(C(C=C)=O)C3=CC=CC=C3S2)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Int Immunopharmacol

Identification of cardiotoxic targets of doxorubicin via network toxicology and development of exosome-based delivery system for osteosarcoma therapy. [Abstract]

2025 Aug 28:161:115011. PMID: 40466611

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (305.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0546 mL

15.2732 mL

30.5465 mL

5 mM

0.6109 mL

3.0546 mL

6.1093 mL

10 mM

0.3055 mL

1.5273 mL

3.0546 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang P, et, al. Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia. J Med Chem. 2021 May 24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0546 mL	15.2732 mL	30.5465 mL	76.3662 mL
	5 mM	0.6109 mL	3.0546 mL	6.1093 mL	15.2732 mL
	10 mM	0.3055 mL	1.5273 mL	3.0546 mL	7.6366 mL
	15 mM	0.2036 mL	1.0182 mL	2.0364 mL	5.0911 mL
	20 mM	0.1527 mL	0.7637 mL	1.5273 mL	3.8183 mL
	25 mM	0.1222 mL	0.6109 mL	1.2219 mL	3.0546 mL
	30 mM	0.1018 mL	0.5091 mL	1.0182 mL	2.5455 mL
	40 mM	0.0764 mL	0.3818 mL	0.7637 mL	1.9092 mL
	50 mM	0.0611 mL	0.3055 mL	0.6109 mL	1.5273 mL
	60 mM	0.0509 mL	0.2546 mL	0.5091 mL	1.2728 mL
	80 mM	0.0382 mL	0.1909 mL	0.3818 mL	0.9546 mL
	100 mM	0.0305 mL	0.1527 mL	0.3055 mL	0.7637 mL

Keywords

GSK-3β inhibitor 3

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

GSK-3β inhibitor 3

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) GSK-3β inhibitor 3

All GSK-3 Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

GSK-3β inhibitor 3 Related Classifications

HY-141480 Related Classifications